Dear colleagues,
We hope you had a pleasant summer.
With our September newsletter, we would like to take a look at the most severe reactions reported to the Anaphylaxis Register (Grade III versus (almost) deadly Grade IV). Please read more about it in the newsletter archive after a successful login. We wish you all a colorful autumn.
Your Anaphylaxis Team
Status: Friday, 06. October 2023
13012 completed cases
| Male patients | 6073 | 47% |
| Female patients | 6939 | 53% |
| Children and youths | 3084 | 24% |
| Adults | 9928 | 76% |
completed cases per country:
| Germany | 9569 | 74% |
| Austria | 1096 | 8% |
| Switzerland | 2347 | 18% |
1825 completed cases
| Male patients | 990 | 54% |
| Female patients | 835 | 46% |
| Children and youths | 833 | 46% |
| Adults | 992 | 54% |
3050 completed cases
| Male patients | 1688 | 55% |
| Female patients | 1362 | 45% |
| Children and youths | 1249 | 41% |
| Adults | 1801 | 59% |
completed cases per country:
| Brazil | 223 | 7% |
| Bulgaria | 255 | 8% |
| Greece | 422 | 14% |
| Ireland | 215 | 7% |
| Italy | 811 | 27% |
| Poland | 434 | 14% |
| Spain | 605 | 20% |
| Romania | 81 | 3% |
| Netherlands | 1 | 0% |
| Croatia | 3 | 0% |
316 completed cases
| Male patients | 170 | 54% |
| Female patients | 146 | 46% |
| Children and youths | 274 | 87% |
| Adults | 42 | 13% |
